www.fdanews.com/articles/157961-celator-pharma-initiates-clinical-study-in-patients-with-untreated-mds-aml

Celator Pharma Initiates Clinical Study in Patients With Untreated MDS/AML

August 16, 2013

Celator is enrolling patients in a trial to test CPX-351 injections for patients with untreated high-risk myelodysplastic syndrome or acute myeloid leukemia.
Pharmabiz.com